HK1251481A1 - 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 - Google Patents

使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 Download PDF

Info

Publication number
HK1251481A1
HK1251481A1 HK18111096.0A HK18111096A HK1251481A1 HK 1251481 A1 HK1251481 A1 HK 1251481A1 HK 18111096 A HK18111096 A HK 18111096A HK 1251481 A1 HK1251481 A1 HK 1251481A1
Authority
HK
Hong Kong
Prior art keywords
antagonists
methods
patients
interleukin
treating non
Prior art date
Application number
HK18111096.0A
Other languages
English (en)
Chinese (zh)
Inventor
Christian Mann
Brian Porter
Hanno Richards
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1251481A1 publication Critical patent/HK1251481A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18111096.0A 2015-10-19 2016-10-14 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 HK1251481A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562243381P 2015-10-19 2015-10-19
US62/243,381 2015-10-19

Publications (1)

Publication Number Publication Date
HK1251481A1 true HK1251481A1 (zh) 2019-02-01

Family

ID=57223732

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111096.0A HK1251481A1 (zh) 2015-10-19 2016-10-14 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法

Country Status (11)

Country Link
US (2) US20190330328A1 (enExample)
EP (1) EP3365011A1 (enExample)
JP (4) JP6858766B2 (enExample)
KR (1) KR20180064415A (enExample)
CN (1) CN108367074A (enExample)
AU (4) AU2016342578A1 (enExample)
CA (1) CA3002622A1 (enExample)
HK (1) HK1251481A1 (enExample)
IL (2) IL297775A (enExample)
RU (2) RU2020124276A (enExample)
WO (1) WO2017068472A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2665954C1 (ru) 2010-10-08 2018-09-05 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6858766B2 (ja) * 2015-10-19 2021-04-14 ノバルティス アーゲー インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
MY207225A (en) 2015-10-27 2025-02-06 UCB Biopharma SRL Methods of treatment using anti-il-17a/f antibodies
EP3641813A4 (en) 2017-06-18 2021-04-21 Kindred Biosciences, Inc. IL17A ANTIBODIES AND ANTAGONISTS FOR USE IN VETERINARY MEDICINE
CA3071337A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP4591879A3 (en) 2019-01-31 2025-10-22 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3963541A1 (en) * 2019-04-29 2022-03-09 UCB Biopharma SRL Medical image analysis system and method for identification of lesions
CA3155108A1 (en) * 2019-09-20 2021-03-25 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
CA3196991A1 (en) * 2020-11-05 2022-05-12 Florence Wing Ling Tsui Methods for systematically assessing local inflammation and active repair
EP4471427A1 (en) * 2023-05-31 2024-12-04 Centre Hospitalier Universitaire De Nice Biomarker for spondyloarthitis diagnostic and response to treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
TWI616204B (zh) * 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
KR20150010709A (ko) * 2012-04-20 2015-01-28 노파르티스 아게 Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
JP6858766B2 (ja) * 2015-10-19 2021-04-14 ノバルティス アーゲー インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法

Also Published As

Publication number Publication date
IL257723B (en) 2022-12-01
CN108367074A (zh) 2018-08-03
IL297775A (en) 2022-12-01
RU2020124276A3 (enExample) 2022-01-18
WO2017068472A1 (en) 2017-04-27
KR20180064415A (ko) 2018-06-14
RU2728710C2 (ru) 2020-07-30
RU2020124276A (ru) 2021-08-03
IL257723A (en) 2018-04-30
CA3002622A1 (en) 2017-04-27
US20250066466A1 (en) 2025-02-27
AU2016342578A1 (en) 2018-03-29
RU2018118177A (ru) 2019-11-21
JP6858766B2 (ja) 2021-04-14
AU2024278118A1 (en) 2025-01-02
JP2026010006A (ja) 2026-01-21
US20190330328A1 (en) 2019-10-31
AU2021240290A1 (en) 2021-11-11
JP2023134701A (ja) 2023-09-27
IL257723B2 (en) 2023-04-01
AU2019240551A1 (en) 2019-10-17
JP7389077B2 (ja) 2023-11-29
EP3365011A1 (en) 2018-08-29
JP2018537418A (ja) 2018-12-20
RU2018118177A3 (enExample) 2020-02-17
JP2021100956A (ja) 2021-07-08

Similar Documents

Publication Publication Date Title
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
MX378273B (es) Compuestos activos hacia bromodominios.
MY187047A (en) Selective pyy compounds and uses thereof
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
IN2013MU03583A (enExample)
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EP4477265A3 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EP4406554A3 (en) Anti-cd3 antibody formulations
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
WO2015161267A3 (en) Humanized and chimeric monoclonal antibodies to cd99
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
WO2014121137A3 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.